Denali Therapeutics (NASDAQ:DNLI) has received a consensus broker rating score of 1.83 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. Denali Therapeutics’ rating score has declined by 56.4% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price objective of $25.33 for the company and are forecasting that the company will post ($0.03) EPS for the current quarter, according to Zacks. Zacks has also given Denali Therapeutics an industry rank of 178 out of 265 based on the ratings given to related companies.
A number of research firms recently issued reports on DNLI. Zacks Investment Research raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Tuesday, April 3rd. Evercore ISI began coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They set an “outperform” rating and a $23.00 price target on the stock. Goldman Sachs began coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They set a “neutral” rating on the stock. Morgan Stanley began coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They set an “overweight” rating and a $25.00 price target on the stock. Finally, JPMorgan Chase began coverage on Denali Therapeutics in a report on Tuesday, January 2nd. They set an “overweight” rating and a $24.00 price target on the stock.
Shares of NASDAQ DNLI traded down $0.58 during midday trading on Monday, reaching $18.62. 106,217 shares of the company were exchanged, compared to its average volume of 295,968. Denali Therapeutics has a 1 year low of $14.72 and a 1 year high of $25.79. The firm has a market cap of $1,813.04 and a P/E ratio of -3.16.
Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Monday, March 19th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.47). equities analysts forecast that Denali Therapeutics will post -0.56 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/04/16/zacks-denali-therapeutics-dnli-receives-consensus-rating-of-buy-from-analysts.html.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.